referral criteria from primary care - infantile haemangioma (haemangiomas)

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

Immediate referral of infantile haemangiomas is indicated if (1):

  • active bleeding or clinical compromise (eg, tachycardia, stridor, cardiac murmur, absent femoral pulses)
  • beard distribution infantile haemangiomas and stridor: risk of obstructive airway haemangiomas (requires ear, nose, and throat assessment)
  • uncontrolled pain from ulcerated lesions

There are 5 major indications for consideration of early treatment or need for further evaluation of infantile haemangiomas (IH):

  • 1) life-threatening complications
    • include obstructing IHs of the airway, liver IHs associated with high-output congestive heart failure and severe hypothyroidism, and, rarely, profuse bleeding from an ulcerated IH
      • obstructing IHs of the airway
        • typically involve the subglottis, further compromising the narrowest portion of the pediatric airway
        • although the mean age at the time of diagnosis is about 4 months, symptoms usually present much earlier but are often mistaken as infectious or inflammatory croup or reactive airway disease
        • most children who are affected develop biphasic stridor and barky cough as the IH enlarges
        • segmental IH of the lower face ("beard distribution") or anterior neck and oral and/or pharyngeal mucosal IHs are the greatest risk factors for an airway IH
    • a consumptive form of hypothyroidism caused by the inactivation of thyroid hormones by type 3 iodothyronine deiodinase present in IH tissue can also be a complication of multifocal or diffuse hepatic IH

  • 2) functional impairment or risk thereof
    • examples of functional impairment include visual disturbance and interference with feeding because of IH involvement of the lips or mouth (1,2)
      • periocular infantile haemangiomas; can result in astigmatism, anisometropia (where the refractive error differs between the two eyes), proptosis (bulging or protruding eyeballs), or amblyopia (inability to see clearly through one eye- also known as "lazy eye")
        • specific characteristics that place an infant at a higher risk for amblyopia include an IH size of >1 cm, upper eyelid involvement, associated ptosis, eyelid margin changes, medial location, and segmental morphology or displacement of the globe
      • lip or oral cavity haemangiomas; can result in breathing or feeding difficulties
      • more than five cutaneous haemangiomas; requires prompt further assessment for liver haemangiomas. Large liver haemangiomas can result in cardiac failure or consumptive hypothyroidism (1)

  • 3) ulceration or risk thereof (1,2)
    • skin or mucosal ulceration of the IH surface occurs with an estimated incidence of 5% to 21% in referral populations
    • ulceration can lead to significant pain, bleeding, and secondary infection and virtually always results in scarring
    • ulceration occurs most frequently in infants younger than 4 months, during the period of active IH proliferation
    • IH associated with a high risk of ulceration (1)
      • segmental infantile haemangiomas >5 cm in size
      • haemangiomas of intertriginous sites or areas of frequent friction:
        • lips, columella, superior helix of ear, gluteal cleft, and/or perineum, perianal skin

  • 4) evaluation to identify important associated structural anomalies
    • a small subset of children with IHs have associated congenital anomalies
    • PHACE syndrome (OMIM 606519)
      • Posterior fossa and other structural brain malformations; large haemangiomas of the face, neck, and/or scalp; anomalies of cerebral or cervical
        arteries; cardiac anomalies/coarctation of the aorta; eye abnormalities and sternal clefting or supraumbilical raphe
      • acronym "PHACES" is sometimes used instead to include potential ventral midline defects, specifically sternal cleft and/or supraumbilical raphe (2)
      • crebrovascular anomalies, present in more than 90% of patients with PHACE syndrome, are the most common extracutaneous feature of the syndrome, followed by cardiac anomalies (67%) and structural brain anomalies (52%) (2)
      • risk of PHACE syndrome in an infant presenting with a large segmental IH of the head or neck is approximately 30% (2)
    • LUMBAR syndrome
      • lower body haemangioma, urogenital abnormalities/ulceration, myelopathy, bony deformities, anorectal malformations
      • may best be viewed as the "lower half of the body" equivalent of PHACE syndrome (2)
        • IHs in LUMBAR syndrome are almost invariably segmental, involving the lumbosacral or perineal skin and often extending onto 1 leg

  • 5) risk of leaving permanent scarring or distortion of anatomic landmarks
    • IHs can lead to permanent disfigurement either via scarring of the skin or distortion of anatomic landmarks
    • risk of disfigurement is much higher than the risk of functional or life-threatening consequences
    • measurements refer to infants under 6 months
      • facial infantile haemangiomas: risk of disfigurement via distortion of anatomical landmarks, scarring, or permanent skin changes
      • haemangiomas on nasal tip or lip and those >2 cm at any other facial location (or >1 cm if baby is 3 months or younger)
      • scalp infantile haemangiomas >2 cm: permanent alopecia (especially if the haemangioma becomes thick or bulky); also risk of profuse bleeding if ulcerates (typically more bleeding than at other sites)
      • neck, trunk, or extremity infantile haemangiomas >2 cm, especially if early in growth phase or if there is an abrupt transition from normal to affected skin (ledge effect): Greater risk of leaving permanent skin changes depending on anatomical location
      • breast infantile haemangiomas (female infants): problems with breast development (eg, breast asymmetry) or nipple contour

Reference:

  • Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas BMJ 2022; 378 :e068734 doi:10.1136/bmj-2021-068734
  • Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A, Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA; SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019 Jan;143(1):e20183475.

Last edited 07/2022 and last reviewed 07/2022

Links: